Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 4/20 | 0.47 |
| ▸ | AR | P10275 | 4/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.35 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13062432 | 0.88 | PGR (0.62) | PGRARNR3C2 | |
| SCHEMBL13062173 | 0.85 | PGR (0.49) | PGRARMEN1KMT2ANR3C2 | |
| SCHEMBL13062496 | 0.84 | PGR (0.47) | PGRARNR3C2 | |
| SCHEMBL12942814 | 0.79 | PGR (0.58) | PGRARNR3C2 | |
| SCHEMBL13062168 | 0.78 | PGR (0.36) | PGRARMEN1KMT2AAKR1C3 | |
| SCHEMBL16715981 | 0.78 | AR (0.59) | PGRARNR3C2 | |
| SCHEMBL13062171 | 0.78 | MEN1 (0.37) | PGRARMEN1KMT2ANR3C2 | |
| SCHEMBL13062447 | 0.75 | AR (0.37) | PGRARMEN1KMT2ANR3C2 | |
| SCHEMBL13062170 | 0.75 | AR (0.50) | PGRARMEN1KMT2ANR3C2 | |
| SCHEMBL13062179 | 0.75 | AR (0.50) | PGRARNR3C2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100317632-A1 | 17-(1'PROPENYL)-17-3'-OXIDOESTRA-4-EN-3-ONE DERIVATIVE, USE THEREOF, AND MEDICAMENT CONTAINING SAID DERIVATIVE | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT | 2010-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317632-A1 | 17-(1'PROPENYL)-17-3'-OXIDOESTRA-4-EN-3-ONE DERIVATIVE, USE THEREOF, AND MEDICAMENT CONTAINING SAID DERIVATIVE | NR5A1, CYP19A1, CYP17A1 | PGR 8/4885AR 44/4885MEN1 618/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.